LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Novo Nordisk A-S

Open

SectorHealthcare

56.49 0.68

Overview

Share price change

24h

Current

Min

56.26

Max

56.5

Key metrics

By Trading Economics

Income

-2.5B

27B

Sales

-1.2B

77B

P/E

Sector Avg

14.483

35.724

EPS

6.53

Dividend yield

3.03

Profit margin

34.484

Employees

78,387

EBITDA

-2.5B

44B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.68% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.03%

3.09%

Market Stats

By TradingEconomics

Market Cap

28B

244B

Previous open

55.81

Previous close

56.49

News Sentiment

By Acuity

84%

16%

358 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Novo Nordisk A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 sie 2025, 13:52 UTC

Major Market Movers

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 sie 2025, 09:23 UTC

Major Market Movers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 sie 2025, 09:23 UTC

Major Market Movers

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 sie 2025, 06:52 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 sie 2025, 06:21 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

21 sie 2025, 08:49 UTC

Earnings
Hot Stocks

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 sie 2025, 09:23 UTC

Hot Stocks

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 sie 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 sie 2025, 11:32 UTC

Earnings

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 sie 2025, 11:03 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 sie 2025, 10:41 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 sie 2025, 20:34 UTC

Earnings

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 sie 2025, 08:45 UTC

Earnings

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 sie 2025, 07:19 UTC

Market Talk
Earnings

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 sie 2025, 05:50 UTC

Earnings

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 sie 2025, 05:48 UTC

Earnings

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 sie 2025, 05:46 UTC

Earnings

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 sie 2025, 05:38 UTC

Earnings

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 sie 2025, 05:37 UTC

Earnings

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 sie 2025, 05:36 UTC

Earnings

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 sie 2025, 05:35 UTC

Earnings

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 sie 2025, 05:34 UTC

Earnings

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6 sie 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Net Pft DKK26.5B

6 sie 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Oper Pft DKK33.45B

6 sie 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Sales DKK76.86B

5 sie 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 sie 2025, 17:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 sie 2025, 15:15 UTC

Earnings

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5 sie 2025, 10:07 UTC

Market Talk

Novo Nordisk's Facing Challenging Times -- Market Talk

1 sie 2025, 11:10 UTC

Hot Stocks

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

19.68% upside

12 Months Forecast

Average 67.57 USD  19.68%

High 90 USD

Low 50 USD

Based on 7 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

2

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

62.63 / 69.23Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

358 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.